verve therapeutics - Search News

Order byBest matchMost fresh

News

Lilly to buy gene-editing partner Verve

Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion

Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, paying $10.50 per share in cash plus a contingent rig

Continue reading

Eli Lilly to buy gene-editing biotech Verve for $1.3 billion

BioPharma Dive · 1h

Lilly to acquire Verve in $1B bet on gene editing for heart disease

1hon MSN

These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, T-Mobile, Lennar, Jabil, and More

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

2hon MSN

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

5h

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company ...

1h

Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday

Trading legend Tom Gentile—who’s trained over 300,000 investors—goes live June 18 at 6 PM ET to reveal the market’s hidden ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results